Literature DB >> 28801055

Therapy with mesenchymal stromal cells or conditioned medium reverse cardiac alterations in a high-fat diet-induced obesity model.

P S Daltro1, B C Barreto2, P G Silva3, P Chenaud Neto3, P H F Sousa Filho3, D Santana Neta3, G B Carvalho4, D N Silva4, B D Paredes4, A C de Alcantara4, L A R Freitas5, R D Couto6, R R Santos7, B S F Souza8, M B P Soares8, S G Macambira9.   

Abstract

BACKGROUND: Obesity is associated with numerous cardiac complications, including arrhythmias, cardiac fibrosis, remodeling and heart failure. Here we evaluated the therapeutic potential of mesenchymal stromal cells (MSCs) and their conditioned medium (CM) to treat cardiac complications in a mouse model of high-fat diet (HFD)-induced obesity.
METHODS: After obesity induction and HFD withdrawal, obese mice were treated with MSCs, CM or vehicle. Cardiac function was assessed using electrocardiography, echocardiography and treadmill test. Body weight and biochemical parameters were evaluated. Cardiac tissue was used for real time (RT)-polymerase chain reaction (PCR) and histopathologic analysis. RESULTS/DISCUSSION: Characterization of CM by protein array showed the presence of different cytokines and growth factors, including chemokines, osteopontin, cystatin C, Serpin E1 and Gas 6. HFD-fed mice presented cardiac arrhythmias, altered cardiac gene expression and fibrosis reflected in physical exercise incapacity associated with obesity and diabetes. Administration of MSCs or CM improved arrhythmias and exercise capacity. This functional improvement correlated with normalization of GATA4 gene expression in the hearts of MSC- or CM-treated mice. The gene expression of connexin 43, troponin I, adiponectin, transforming growth factor (TGF) β, peroxisome proliferator activated receptor gamma (PPARγ), insulin-like growth factor 1 (IGF-1), matrix metalloproteinase-9 (MMP9) and tissue inhibitor of metalloproteinases 1 (TIMP1) were significantly reduced in MSCs, but not in CM-treated mice. Moreover, MSC or CM administration reduced the intensity of cardiac fibrosis.
CONCLUSION: Our results suggest that MSCs and CM have a recovery effect on cardiac disturbances due to obesity and corroborate to the paracrine action of MSCs in heart disease models.
Copyright © 2017 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac dysfunction; cell therapy; mesenchymal stromal cells; obesity

Mesh:

Substances:

Year:  2017        PMID: 28801055     DOI: 10.1016/j.jcyt.2017.07.002

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  11 in total

Review 1.  Paracrine Factors Released by Stem Cells of Mesenchymal Origin and their Effects in Cardiovascular Disease: A Systematic Review of Pre-clinical Studies.

Authors:  Nishani S Mabotuwana; Lavinia Rech; Joyce Lim; Sean A Hardy; Lucy A Murtha; Peter P Rainer; Andrew J Boyle
Journal:  Stem Cell Rev Rep       Date:  2022-07-28       Impact factor: 6.692

Review 2.  Translating MSC Therapy in the Age of Obesity.

Authors:  Lauren Boland; Laura Melanie Bitterlich; Andrew E Hogan; James A Ankrum; Karen English
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

3.  Cardiomyocyte-specific deletion of GSK-3β leads to cardiac dysfunction in a diet induced obesity model.

Authors:  Manisha Gupte; Samvruta Tumuluru; Jennifer Y Sui; Anand Prakash Singh; Prachi Umbarkar; Shan S Parikh; Firdos Ahmad; Qinkun Zhang; Thomas Force; Hind Lal
Journal:  Int J Cardiol       Date:  2018-02-03       Impact factor: 4.164

4.  Beneficial Effects of Human Mesenchymal Stromal Cells on Porcine Hepatocyte Viability and Albumin Secretion.

Authors:  Elisa Montanari; Joel Pimenta; Luca Szabó; François Noverraz; Solène Passemard; Raphael P H Meier; Jeremy Meyer; Jonathan Sidibe; Aurelien Thomas; Henk-Jan Schuurman; Sandrine Gerber-Lemaire; Carmen Gonelle-Gispert; Leo H Buhler
Journal:  J Immunol Res       Date:  2018-01-11       Impact factor: 4.818

5.  Regenerative potential of partially differentiated mesenchymal stromal cells in a mouse model of a full-thickness skin wound.

Authors:  Ausra Liubaviciute; Vytautas Kaseta; Aida Vaitkuviene; Zygmunt Mackiewicz; Gene Biziuleviciene
Journal:  EXCLI J       Date:  2018-08-31       Impact factor: 4.068

Review 6.  Therapeutic potential of mesenchymal stem cells in multiple organs affected by COVID-19.

Authors:  Gustavo C Paris; Aline A Azevedo; Adriana L Ferreira; Yanca M A Azevedo; Mateus A Rainho; Genilza P Oliveira; Karina R Silva; Erika A C Cortez; Ana C Stumbo; Simone N Carvalho; Lais de Carvalho; Alessandra A Thole
Journal:  Life Sci       Date:  2021-04-15       Impact factor: 6.780

Review 7.  Novel insights into the pathological mechanisms of metabolic related dyslipidemia.

Authors:  Xin Su; Ye Cheng; Guoming Zhang; Bin Wang
Journal:  Mol Biol Rep       Date:  2021-07-04       Impact factor: 2.316

8.  Effect of Adipose derived mesenchymal stem cells on multiple Organ Injuries in diet-induced obese mice.

Authors:  Fatima A Saleh; Hala Jaber; Ali Eid
Journal:  Tissue Barriers       Date:  2021-07-25

9.  Corneal Mesenchymal Stromal Cells Are Directly Antiangiogenic via PEDF and sFLT-1.

Authors:  Medi Eslani; Ilham Putra; Xiang Shen; Judy Hamouie; Neda Afsharkhamseh; Soroush Besharat; Mark I Rosenblatt; Reza Dana; Peiman Hematti; Ali R Djalilian
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-10-01       Impact factor: 4.799

10.  Bone Marrow-Derived Mesenchymal Stem Cells Restored High-Fat-Fed Induced Hyperinsulinemia in Rats at Early Stage of Type 2 Diabetes Mellitus.

Authors:  Gongchi Li; Han Peng; Shen Qian; Xinhua Zou; Ye Du; Zhi Wang; Lijun Zou; Zibo Feng; Jing Zhang; Youpeng Zhu; Huamin Liang; Binghui Li
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.